Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Guohui Han, Ph.D.
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Jinfeng Ma
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Qing Yan
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Jianzhong Cao
Recruiting
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
NCT07640295· Phase 1/2· Jacobio Pharmaceuticals Co., Ltd.· Source
Contact: ShanXi Cancer Hospital
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Wei Guo (principal investigator)
Recruiting
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Jing Jin, M.D.
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766· Phase 3· Genmab· Source
Active, not recruiting
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Not yet recruiting
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Ruyuan Guo, Master
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Contact: Yinping Zhong
Not yet recruiting
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
NCT07486648· Phase 1/2· Shanxi Province Cancer Hospital· Source
Contact: Jinfang Zhai
Recruiting
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143· Phase 2/3· RemeGen Co., Ltd.· Source
Contact: Hongfang Li
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Wenhui Yang, Doctor
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Jianghua Wei, Master
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Hongwei Li, Site 0542
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xin Wang, Doctor
Active, not recruiting
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923· Phase 1· Hansoh BioMedical R&D Company· Source
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236· Phase 2· Fujian Cancer Hospital· Source
Contact: Qin Xu, Ph.D
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Hongxia Lu, Doctor
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822· Phase 2· Peking University· Source
Contact: Hongxia Lu
Active, not recruiting
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source
Recruiting
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Qingxian Huang
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source
Contact: wei guo, Site 0258
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Guohui Han, Site 1018
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994· Phase 1/2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Study Coordinator
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Qinxiang Guo
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679· Phase 2/3· Beijing Biostar Pharmaceuticals Co., Ltd.· Source
Contact: Wenhui Yang (principal investigator)
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650· Phase 1/2· Dizal Pharmaceuticals· Source
Contact: Su
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936· Phase 1/2· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source
Contact: Meiping Kong
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Guohui Han, Master
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Recruiting
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865· Phase 2· RemeGen Co., Ltd.· Source
Contact: Heping Liu
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Guohui Han, Master
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Jinfeng Ma
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Hongwei Li, M.D.
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Jianchun Duan, Site 0353
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Liping Su, Doctor
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Guohui Han
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324· Phase 3· Nuvation Bio Inc.· Source
Contact: Wei Guo
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615· Phase 1/2· Jacobio Pharmaceuticals Co., Ltd.· Source
Contact: Jacobio Pharmaceuticals
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: wei guo, Site 0435
Showing 50 of 81.